139 related articles for article (PubMed ID: 35533035)
1. Open-Label Cohort Study to Evaluate Efficacy and Safety of Application of Glycopyrronium Cloth, 2.4% for Palmar Hyperhidrosis.
Pariser D; Rivera E; Benedict D
J Drugs Dermatol; 2022 May; 21(5):488-495. PubMed ID: 35533035
[TBL] [Abstract][Full Text] [Related]
2. A 44-Week Open-Label Study Evaluating Safety and Efficacy of Topical Glycopyrronium Tosylate in Patients with Primary Axillary Hyperhidrosis.
Glaser DA; Hebert AA; Nast A; Werschler WP; Green L; Mamelok RD; Quiring J; Drew J; Pariser DM
Am J Clin Dermatol; 2019 Aug; 20(4):593-604. PubMed ID: 31111409
[TBL] [Abstract][Full Text] [Related]
3. Limited Systemic Exposure with Topical Glycopyrronium Tosylate in Primary Axillary Hyperhidrosis.
Pariser DM; Lain EL; Mamelok RD; Drew J; Mould DR
Clin Pharmacokinet; 2021 May; 60(5):665-676. PubMed ID: 33433785
[TBL] [Abstract][Full Text] [Related]
4. Long-term efficacy and safety of topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: Post hoc pediatric subgroup analysis from a 44-week open-label extension study.
Hebert AA; Glaser DA; Green L; Hull C; Cather J; Drew J; Gopalan R; Pariser DM
Pediatr Dermatol; 2020 May; 37(3):490-497. PubMed ID: 32147881
[TBL] [Abstract][Full Text] [Related]
5. Topical glycopyrronium tosylate in Japanese patients with primary axillary hyperhidrosis: A randomized, double-blind, vehicle-controlled study.
Yokozeki H; Fujimoto T; Wanatabe S; Ogawa S; Fujii C
J Dermatol; 2022 Jan; 49(1):86-94. PubMed ID: 34636057
[TBL] [Abstract][Full Text] [Related]
6. Variables Affecting Delivery of Glycopyrronium Tosylate Through Human Skin In Vitro.
Caserta F; Lenn J; Hofland H
J Drugs Dermatol; 2020 Nov; 19(11):1080-1085. PubMed ID: 33196749
[TBL] [Abstract][Full Text] [Related]
7. Topical Glycopyrronium Tosylate for the Treatment of Primary Axillary Hyperhidrosis: Patient-Reported Outcomes from the ATMOS-1 and ATMOS-2 Phase III Randomized Controlled Trials.
Pariser DM; Hebert AA; Drew J; Quiring J; Gopalan R; Glaser DA
Am J Clin Dermatol; 2019 Feb; 20(1):135-145. PubMed ID: 30378087
[TBL] [Abstract][Full Text] [Related]
8. Glycopyrronium tosylate in pediatric primary axillary hyperhidrosis: Post hoc analysis of efficacy and safety findings by age from two phase three randomized controlled trials.
Hebert AA; Glaser DA; Green L; Werschler WP; Forsha DW; Drew J; Gopalan R; Pariser DM
Pediatr Dermatol; 2019 Jan; 36(1):89-99. PubMed ID: 30451318
[TBL] [Abstract][Full Text] [Related]
9. A glycopyrronium bromide 1% cream for topical treatment of primary axillary hyperhidrosis: efficacy and safety results from a phase IIIa randomized controlled trial.
Abels C; Soeberdt M; Kilic A; Reich H; Knie U; Jourdan C; Schramm K; Heimstaedt-Muskett S; Masur C; Szeimies RM
Br J Dermatol; 2021 Aug; 185(2):315-322. PubMed ID: 33445205
[TBL] [Abstract][Full Text] [Related]
10. Qbrexza - A glycopyrronium cloth for axillary hyperhidrosis.
Med Lett Drugs Ther; 2019 Jan; 61(1564):10-11. PubMed ID: 30856158
[No Abstract] [Full Text] [Related]
11. Long-term efficacy and safety of 1% glycopyrronium bromide cream in patients with severe primary axillary hyperhidrosis: Results from a Phase 3b trial.
Szeimies RM; Abels C; Kilic A; Reich H; Berger B; Schulze Zur Wiesche E; Schramm K; Litzka L; Heimstaedt-Muskett S; Masur C
J Eur Acad Dermatol Venereol; 2023 Apr; 37(4):823-830. PubMed ID: 36606529
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of iontophoresis with glycopyrronium bromide for treatment of primary palmar hyperhidrosis.
Chia HY; Tan AS; Chong WS; Tey HL
J Eur Acad Dermatol Venereol; 2012 Sep; 26(9):1167-70. PubMed ID: 21812834
[TBL] [Abstract][Full Text] [Related]
13. Topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: Results from the ATMOS-1 and ATMOS-2 phase 3 randomized controlled trials.
Glaser DA; Hebert AA; Nast A; Werschler WP; Green L; Mamelok R; Drew J; Quiring J; Pariser DM
J Am Acad Dermatol; 2019 Jan; 80(1):128-138.e2. PubMed ID: 30003988
[TBL] [Abstract][Full Text] [Related]
14. Glycopyrronium Tosylate (Qbrexza) for Hyperhidrosis.
Nwannunu CE; Limmer AL; Coleman K; Shah R; Patel RR; Mui UN; Tyring SK
Skin Therapy Lett; 2019 Mar; 24(2):1-3. PubMed ID: 30970203
[TBL] [Abstract][Full Text] [Related]
15. Use of gloves when applying topical glycopyrronium for treatment of primary axillary hyperhidrosis.
Siscos SM; Figenshau K; Rajpara A
J Am Acad Dermatol; 2020 Oct; 83(4):e275. PubMed ID: 31846717
[No Abstract] [Full Text] [Related]
16. Topical Glycopyrronium Tosylate in Primary Axillary Hyperhidrosis: A Profile of Its Use.
Lamb YN
Clin Drug Investig; 2019 Nov; 39(11):1141-1147. PubMed ID: 31571127
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of a new aluminium salt thermophobic foam in the treatment of axillary and palmar primary hyperhidrosis: a pilot exploratory trial.
Innocenzi D; Lupi F; Bruni F; Frasca M; Panetta C; Milani M
Curr Med Res Opin; 2005 Dec; 21(12):1949-53. PubMed ID: 16368045
[TBL] [Abstract][Full Text] [Related]
18. Use of oral glycopyrronium bromide in hyperhidrosis.
Bajaj V; Langtry JA
Br J Dermatol; 2007 Jul; 157(1):118-21. PubMed ID: 17459043
[TBL] [Abstract][Full Text] [Related]
19. Double-blind, randomized, placebo-controlled pilot study of the safety and efficacy of Myobloc (botulinum toxin type B) for the treatment of palmar hyperhidrosis.
Baumann L; Slezinger A; Halem M; Vujevich J; Mallin K; Charles C; Martin LK; Black L; Bryde J
Dermatol Surg; 2005 Mar; 31(3):263-70. PubMed ID: 15841624
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of topical formulations containing 0ยท5, 1 and 2% glycopyrronium bromide in patients with primary axillary hyperhidrosis: a randomized, double-blind, placebo-controlled study.
Masur C; Soeberdt M; Kilic A; Knie U; Abels C
Br J Dermatol; 2020 Jan; 182(1):229-231. PubMed ID: 31218668
[No Abstract] [Full Text] [Related]
[Next] [New Search]
